Together, Risklick and Citeline deliver an integrated, intelligent protocol development experience that combines smart authoring with AI-powered optimization, directly in the workflow.​ The result is ...

In this free webinar, understand the key benefits of master protocols. Attendees will identify the key challenges of master protocols and strategies to address them. The featured speakers will discuss ...

The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

The integration of real-world data (RWD) into protocol feasibility and site selection has emerged as a clinical trial game-changer in recent years. Traditionally relying heavily on data from carefully ...

Most pharmaceutical manufacturers utilize the gold standard of clinical trial design: randomized, controlled trials (RCTs) executed in four phases. Any protocols used must be approved by the FDA under ...

Successful clinical trial conduct balances participant safety, treatment efficacy and operational feasibility. But slow patient identification and enrollment, cost overruns and missed deadlines pose a ...

BOSTON--(BUSINESS WIRE)--Transparency Life Sciences (TLS) today announced the debut of a novel patient-centric protocol builder for clinical trials called Transparency Protocol Crowdsourcing© (TPC). A ...

About the Author: Jack is a marketing and community associate at Dreamit, where he focuses on sourcing and evaluating health tech startups and creating opportunities for Dreamit to engage with the ...

The flowchart and steps below outlines the best practice for processing industry-written and sponsored clinical trials at UAB. There are many small steps in each of the larger defined steps (see flow ...

As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting ...

An international group of cancer researchers, led by the National Cancer Research Institute's (NCRI) Cellular Molecular Pathology Initiative (CMPath), has published guidance to address the variability ...